ArticleThe Journal of asthma : official journal of the Association for the Care of Asthma2026
Effect of IL-4RαR576 polymorphism on response to dupilumab in asthma, a genotype-stratified, randomized, placebo- controlled trial (IDEA trial): design, rationale, methods, strategies, and lessons learned.
Article in The Journal of asthma : official journal of the Association for the Care of Asthma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Controlling and Preventing Asthma Progression and Severity in Kids
Effect of IL-4RαR576 Polymorphism on Response to Dupilumab in Asthma, a Genotype-stratified, Randomized, Placebo- Controlled Trial
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
BACKGROUND/
objectiveAsthma is a heterogeneous chronic disease, disproportionately affecting racial and ethnic minorities, with persistence and severity influenced by both environmental and genetic factors. The IL-4RαR576 variant occurs more commonly in racially minoritized, and the genotype, independent of race, is associated with severe, exacerbation-prone asthma. IDEA (Investigating Dupilumab's Effect in Asthma by genotype) NCT02570984 is a multicenter, randomized, placebo-controlled trial designed to determine whether dupilumab, a monoclonal antibody that directly inhibits the IL-4 receptor, has differential efficacy according to IL-4Rα genotype, and to better understand genotype-specific asthma outcomes in adolescents and adults. At the time of this design and methods report, while enrollment is closed, the trial is ongoing and clinical outcome results are not yet available.
methodsIDEA enrolled participants aged 12 years and above with uncontrolled asthma. Eligible participants are genotyped for the IL-4RαR576 allele and stratified into wild-type, heterozygous, and homozygous groups. A total of 120 participants (goal of 48 wild-type, 48 heterozygous, 24 homozygous) are being randomized 1:1 to receive dupilumab or placebo in addition to guidelines-based therapy for 48 wk. The primary endpoint is reduction in asthma exacerbations. Digitalized strategies to address adherence in home administration of biologics are employed. Strategies to boost recruitment include new electronic health medical record tools, community advertising on public transportation and subway systems, and team members and sites in culturally attuned neighborhoods.
conclusionsIDEA evaluates response to a biologic by genotype. Results will inform future targeted therapies in genetically susceptible populations, with potential implications for reducing asthma disparities.Clinical Trials.gov NCT03694158.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.